IPE Approved to Begin Phase-2 Clinical Trials for New Thyroid Drug

Intellectual Property Executives, IPE, a VT KnowledgeWorks member company, announced that it has been given approval by the U.S. Food and Drug Administration to begin Phase-2 clinical trials for BCT303, its lead T3 candidate to treat hypothyroidism.

IPE is a family-owned and operated pharmaceutical drug discovery and development company located in Kingsport, Tennessee, USA.

Read the full press release here.

Keep in the know about VT KnowledgeWorks through Twitter and Facebook.

VT KnowledgeWorksVT KnowledgeWorks encourages and enables creative entrepreneurship world-wide, through innovative curriculum, local business resource centers, and a global network of cooperating regions, all focused on three essential contributors to success: clear understanding of fundamental business principles; access to timely, relevant information; and meaningful personal and corporate relationships. It is a subsidiary of the Virginia Tech Corporate Research Center, supported by the continuing confidence and enthusiasm of its clients, sponsors and friends, both corporate and individual. Its world headquarters are in Blacksburg, Virginia, USA.

VT KnowledgeWorks corporate sponsors include Attaain, Inc., BB&THarris Office FurnitureHodges, Jones & Mabry, P.C.Hutchison Law Group, Latimer IP Law, LLC , LeClairRyanNew River Valley IP Law, Science Applications International Corporation (SAIC)The Branch Group, and Wordsprint.

Speak Your Mind